ContraVir Pharmaceuticals (NASDAQ: CTRV) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare ContraVir Pharmaceuticals to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.
Volatility & Risk
ContraVir Pharmaceuticals has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500. Comparatively, ContraVir Pharmaceuticals’ competitors have a beta of 6.02, indicating that their average share price is 502% more volatile than the S&P 500.
6.7% of ContraVir Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.2% of ContraVir Pharmaceuticals shares are owned by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for ContraVir Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ContraVir Pharmaceuticals Competitors||867||3228||11711||232||2.71|
ContraVir Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 981.08%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.56%. Given ContraVir Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe ContraVir Pharmaceuticals is more favorable than its competitors.
This table compares ContraVir Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ContraVir Pharmaceuticals Competitors||-5,310.12%||-211.56%||-39.37%|
Earnings & Valuation
This table compares ContraVir Pharmaceuticals and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|ContraVir Pharmaceuticals||N/A||-$14.89 million||-0.76|
|ContraVir Pharmaceuticals Competitors||$284.49 million||$34.10 million||81.37|
ContraVir Pharmaceuticals’ competitors have higher revenue and earnings than ContraVir Pharmaceuticals. ContraVir Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
ContraVir Pharmaceuticals competitors beat ContraVir Pharmaceuticals on 8 of the 12 factors compared.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.